Orlistat is an inhibitor of gastrointestinal lipases, leading to reduced fat absorption.
It is licensed for patients with BMI
> 28 with associated risk factors, a weight management programme should be in place. Use is not recommended
for more than 2 years.
-
Ain-Shams Cardiology Department CME(The first online Cardiology systemic review videos in the world from the scratch t... -
Bartter's s y ndrome is an autoso m al reces s ive renal dis o rder. Presentati o n is often in childhood w...
No comments:
Post a Comment